Clinical Trials

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia


Study ID
Millennium Pevonedistat-3001

NCT Number
NCT03268954 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0826

Principle Investigator
Dr. James McCloskey

Phase
III

Sponsor
Millennium


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now